Novo Nordisk: Wegovy Approved in China for MASH Liver Disease

Novo Nordisk announced that Wegovy, used for obesity and diabetes treatment, has received approval in China for the indication of metabolic dysfunction-associated steatohepatitis (MASH). The company stated that it has obtained regulatory approval for the drug's use in this liver disease. MASH is a serious liver disease characterized by fat accumulation, inflammation, and damage in the liver. The approval of Wegovy for this indication expands Novo Nordisk's presence in the field of liver diseases. China, as one of the world's most populous countries, represents a significant market for MASH patients. The approval could enhance the company's access in this region. Wegovy had previously been approved for obesity treatment in various countries. This new approval allows the drug to be used in a different therapeutic area. Not investment advice.

📊 NVO — Piyasa Yorumu

▲ up · 55%

The news that Novo Nordisk's Wegovy has received approval in China for MASH liver disease creates a new market opportunity for the company. However, the stock has fallen 5.8% in the last 24 hours and the RSI is at 26, in oversold territory, which could support short-term buying. The MACD is negative and the price is below the SMA20 and SMA50, indicating a weak technical picture. The impact of the news may be limited as selling pressure persists across the market. Nevertheless, with oversold conditions and positive news combined, a moderate recovery is possible in 1-3 days.

RSI 14

26.1

MACD

-0.47

24h Δ

-5.84%

📊 GOOGL — Piyasa Yorumu

■ neutral · 60%

There is no fundamental impact on GOOGL stock. Technical indicators are already weak: price has fallen 4.18% in 24 hours, RSI at 33.7 is near oversold territory, and MACD is negative. This news does not change GOOGL's current downtrend; a neutral impact is expected in the short term.

RSI 14

33.7

MACD

-2.54

24h Δ

-4.18%

Canlı Grafikler